Monolayer Hematopoietic Differentiation Without Embryoid Bodies
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing methods for differentiating human induced pluripotent stem cells (hiPSCs) to hematopoietic cells are labor-intensive, inefficient, and lack scalability due to the requirement of serum-containing media and the formation of embryoid bodies, leading to heterogeneous cell populations.
Innovation Solution
A monolayer culturing platform using BMP pathway activators, bFGF, and optional WNT pathway activators, along with ROCK and GSK3 inhibitors, to differentiate pluripotent stem cells directly into hematopoietic lineages without embryoid bodies, enabling scalable and homogeneous cell expansion.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If embryoid bodies are formed to differentiate hiPSCs to hematopoietic cells, then differentiation can be induced, but the process becomes labor-intensive and heterogeneous cell populations are produced
Solution Approach 1:
The invention extracts and eliminates the embryoid body formation step from the differentiation protocol. By directly differentiating hiPSCs in monolayer culture without forming 3D embryoid bodies, the method removes the labor-intensive aggregation and dissociation steps while avoiding the heterogeneity problem inherent in EB-based protocols.
Solution Approach 2:
The differentiation process is segmented into distinct sequential stages (mesoderm induction, definitive hematopoietic progenitor generation, and lymphoid effector cell differentiation) that can be controlled independently in monolayer culture, enabling precise temporal and spatial regulation of each developmental transition.
2Reliability
If embryoid bodies are formed for differentiation, then cell aggregation occurs, but cell numbers minimally increase and scalability is hindered
Solution Approach 1:
The invention extracts the limiting factor (embryoid body formation) that prevents cell expansion. By conducting differentiation in monolayer format, the system eliminates the physical constraint of 3D aggregate structure that limits cell number increase, thereby enabling scalable production.
3Reliability
If serum-containing media is used for hiPSC differentiation, then pluripotency maintenance is achieved, but the process lacks scalability and reproducibility
Solution Approach 1:
The invention changes the chemical parameters of the culture media by replacing undefined serum components with defined growth factors and small molecules. This substitution maintains the necessary signaling for pluripotency and differentiation while enabling precise control and scalability of the manufacturing process.
Solution Approach 2:
The invention replaces expensive and variable serum-based media with cost-effective, defined chemical compositions that can be precisely formulated and reproduced. This approach uses readily available reagents in controlled concentrations, eliminating batch-to-batch variability associated with serum.
4Reliability
If aggregates are formed for EB differentiation, then differentiation is facilitated, but the cellular content is exposed to media factors inconsistently leading to heterogeneous products
Solution Approach 1:
The invention extracts the source of heterogeneity (3D aggregate structure) by transitioning to monolayer culture. This eliminates the gradient effects and inconsistent media exposure that occur in embryoid bodies, ensuring uniform delivery of differentiation signals to all cells.
Solution Approach 2:
The invention implements homogeneity by maintaining all cells in a uniform monolayer configuration where every cell experiences identical media exposure and signaling conditions. This uniformity ensures consistent differentiation outcomes across the entire cell population.
Data Source
AI summary
The invention provides culture platforms, cell media, and methods of differentiating pluripotent cells into hematopoietic cells. The invention further provides pluripotent stem cell-derived hematopoietic cells generated using the culture platforms and methods disclosed herein, which enable feed-free, monolayer culturing and in the absence of EB formation. Specifically, pluripotent stem cell-derived hematopoietic cell of this invention include, and not limited to, iHSC, definitive hemogenic endothelium, hematopoietic multipotent progenitors, T cell progenitors, NK cell progenitors, T cells, NK cells, NKT cells and B cells.